<DOC>
	<DOCNO>NCT00003284</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness high-dose combination chemotherapy follow peripheral stem cell transplantation treat patient lung cancer .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate high dose chemotherapy follow autologous peripheral blood stem cell transplantation treatment lung cancer . OUTLINE : Patients undergo stem cell harvest . Patients receive radiation therapy primary site metastatic site , necessary . Patients receive high dose paclitaxel 24 hour continuous infusion , stem cell infuse 72 hour later . After 3-4 week recovery period , patient receive ifosfamide carboplatin daily continuous infusion day -7 , -6 , -5 , -4 . Etoposide administer continuous infusion twice daily day -7 , -6 , -5 , -4 . Stem cell infuse day 0 . Filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) begin day 0 . Patients may receive radiotherapy follow recovery chemotherapy . Patients follow weekly first 6 month , periodically least 2 year . PROJECTED ACCRUAL : This study accrue 30 patient 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically diagnose lung cancer include follow : Relapsed limited stage small cell lung cancer ( SCLC ) Limited stage SCLC respond conventional radiotherapy Extensive stage SCLC Stage IIIB IV nonsmall cell lung cancer ( NSCLC ) Stages IIIIIA NSCLC unable unwilling undergo surgery acceptable candidate high dose chemotherapy Cryopreserved peripheral blood stem cell CD34 count great 2000/mm3 No untreated uncontrolled brain metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 time normal SGOT le 1.5 time normal Renal : Creatinine clearance great 50 mL/min Pulmonary : Left ventricular ejection fraction great 45 % DLCO great 40 % Other : Not pregnant lactate No medical psychiatric illness prevent informed consent intensive treatment PRIOR CONCURRENT THERAPY : Concurrent chemotherapy allow evidence disease progression</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>